Cliantha Research, full-service Clinical Research Organization (CRO), provides comprehensive and integrated offerings in Early Phase, Late Phase, Respiratory, Tobacco Research, Dermatology, Consumer Research, Research Lab, IVRT, Biometrics, Pharmacovigilance & Medical Services, Environmental Exposure Chamber (EECs).
Cliantha, by leveraging on the depth of experience provides ethical, value added customer centric services, thereby enabling clinical development of pharmaceutical, biotech & healthcare companies.
Cliantha has successfully completed its 18th multi-centric site inspection. It was an unannounced inspection & successful completion immaculate our regulatory and quality track record in clinical trials. The inspection was conducted in Osteoarthritis indication at Himmatnagar site between September 17 to 20, 2018 & was concluded without any observation. Clearance of such unannounced inspections depicts our strict adherence to quality parameters.
MedDRA is used by worldwide regulatory authorities in the pharma industry as part of the regulatory process. Currently, the major version of MedDRA is 21.0, which has been updated to 21.1 on 1st September 2018. An internal training was held at Cliantha under the auspices of Dr Ripal Gharia, AGM-PV & Medical Services, where more than 30 members of Cliantha Research Limited participated.
Inflamax Research specializes in the conduct of Phase III clinical studies for respiratory diseases such as asthma and COPD. We have been awarded two large, Phase III clinical endpoint studies in patients with asthma. Particularly, we have experience in helping clients who are developing generic inhaled products realize approvals based on the required clinical studies.